NRG1 (Neuregulin 1) fusion tumors are a rare type of gene fusion-driven cancer, mainly found in lung cancer, breast cancer, pancreatic cancer, and others. The NRG1 gene fusion leads to abnormal activation of signaling pathways through the ERBB family (especially ERBB3 and ERBB2/HER2), which...
NRG1 基因突变与药物 EXPRESSION SDC4-NRG1 SLC3A2-NRG1 ATP1B1-NRG1 fusion NRG1 fusion NRG1 基因突变 NRG1 fusion Allele Registry ID:别名: ClinVar ID: 基因突变位点 Ref. Build: Ensembl Version: null Chr. Start Stop Ref. s Var. Bases null null Transcript 基因序列移动...
1.Jonna S, Feldman RA, Swenson J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25:4966-4972. 2.Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NR...
[3] Cheema, Parneet K., Mark Doherty, and Ming-Sound Tsao. "A case of invasive mucinous pulmonary adenocarcinoma with a CD74-NRG1 fusion protein targeted with afatinib." Journal of Thoracic Oncology 12.12 (2017): e200-e202.[4] Rimer, Mendell. "Neuregulins at the neuromuscular synapse: p...
"A case of invasive mucinous pulmonary adenocarcinoma with a CD74-NRG1 fusion protein targeted with afatinib." Journal of Thoracic Oncology 12.12 (2017): e200-e202.[4] Rimer, Mendell. "Neuregulins at the neuromuscular synapse: past, present, and future." Journal of neuroscience research 85.9 ...
Methods We report a case series of all known patients with NRG1 fusion-positive solid tumors who were treated with afatinib; afatinib therapy is ongoing for some patients. Results To date, 18 patients with NRG1 fusion-positive solid tumors have been treated with afatinib (Table). These include...
6.Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: the eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021;39(25):2791-2802. doi:10.1200/...
Schram A, Goto K, Kim D-W, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(suppl 2):S756-S757. doi:10.1016/j.annonc.2023.09.2349 ...
Schram A, Goto K, Kim D-W, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(suppl 2):S756-S757. doi:10.1016/j.annonc.2023.09.2349 ...
(PTx), a private, fully-integrated biotechnology company with a focus in hematology and oncology, in which Merus has exclusively licensed to PTx the right to commercialize zenocutuzumab (Zeno, tradename Bizengri®) for the treatment of NRG1 fusion-positive (NRG1+) cancer in the United ...